Das Berufsgenossenschaftliche Universitätsklinikum Bergmannsheil gGmbH bildet eine nicht landeseigene Universitätsklinik am Universitätsklinikum der Ruhr-Universität Bochum. Es gehört zur Unternehmensgruppe der BG Kliniken.

During the past decade, Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 16 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 14 clinical trials were completed. i.e. 466.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "Artu Biologicals" with 3 trials sponsored, "Medtronic Bakken Research Center" with 3 trials sponsored, "Ruhr University of Bochum" with 3 trials sponsored and "Boehringer Ingelheim" with 3 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH" #1 collaborator was "Medtronic" with 3 trials as a collaborator, "Biogen" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "CRI-The Clinical Research Institute GmbH" with 1 trials as a collaborator and "Heart Center Leipzig - University Hospital" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH" are "Heart Failure" (4 trials), "Allergic Rhinoconjunctivitis" (3 trials), "Crohn Disease" (3 trials), "Amyotrophic Lateral Sclerosis" (2 trials) and "Asthma" (2 trials). Many other conditions were trialed in "Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH" in a lesser frequency.

Most popular intervention types in "Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH" are "Drug" (19 trials), "Device" (12 trials), "Other" (6 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Etrolizumab" (4 trials), "Oralgen" (3 trials), "Dexpramipexole" (2 trials) and "GED-0301" (2 trials). Other intervention names were less common.

The vast majority of trials in "Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH" are 36 trials for "All" genders.

Currently, there are NaN active trials in "Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 10 trials that are defined as “Not Applicable".